Takeda Chemical Industries, Inc.

Tokyo Metropolitan Institute of Medical Science

Tomofumi Kurokawa

Susumu Iwasa

Shigeyuki Takada

Yukio Toyoda

Kenjiro Tanoue

Hiroh Yamazaki

A sustained-release preparation containing a bioactive polypeptide is prepared using a starting material containing a lyophilized product of an aqueous solution or suspension of the bioactive polypeptide in a non-ionic surfactant. The lyophilized product is dispersed in an oil phase, which further contains a biocompatible, biodegradable polymer.

Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase

A sustained-release microcapsule contains an amorphous water-soluble pharmaceutical agent having a particle size of from 1 nm-10 .mu.m and a polymer. The microcapsule is produced by dispersing, in an aqueous phase, a dispersion of from 0.001-90% (w/w) of an amorphous water-soluble pharmaceutical agent in a solution of a polymer having a wt. avg. molecular weight of 2,000-800,000 in an organic solvent to prepare an s/o/w emulsion and subjecting the emulsion to in-water drying.

Sustained-release microcapsule of amorphous water-soluble pharmaceutical

A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous phase a dispersion of the amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof in a solution of a polymer in an organic solvent to give an s/o/w type emulsion and subjecting the emulsion to in-water drying. The sustained-release microcapsule entraps 2-piperazinone-1-acetic acid compound or the salt thereof, as a drug, in high concentration, and in reducing the initial release of the drug, thereby reducing undesirable side effects of the drug.

Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic

The present invention provides a hybrid monoclonal antibody having specificities against fibrin and thrombolytic substance, a polydoma which produces said antibody and thrombolytic agent comprising said antibody and thrombolytic substance which is immunologically coupled thereto, and methods of using said antibody in combination with thrombolytic substance for lysis or removal of thrombi.

Hybrid monoclonal antibodies, their production and use

Disclosed are a bispecific hybrid MoAb having specificity for both an activated platelet and a substance having thrombolytic activity, and a thrombolytic agent comprising the above bispecific MoAb and a substance having thrombolytic activity immunologically bound thereto, whereby efficient, rapid thrombolysis is possible.

Growing community of inventors

Hyogo, Japan

Tomofumi Kurokawa